Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

Weight-loss drugs that mimic the effect of regulatory hormones on appetite and energy balance often come with a few rather ...

Whether you’re taking Ozempic for type 2 diabetes or for weight loss, you’re probably noticing a lot of changes in your body.

Women who use an oral contraceptive might want to consider using a back-up method after starting a weight loss drug.

New research shows GLP-1 drugs may be linked to a twofold increase in the risk of wet AMD among people with diabetes.

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

Semaglutide use may be increasing worldwide rates of ischemic optic neuropathy and retinal adverse events, a study suggests.

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.